The fat jabs that could halt depression and schizophrenia symptoms in their tracks revealed

Key Points:

• New research published in The Lancet Psychiatry suggests GLP-1 weight loss injections may reduce symptoms of depression and schizophrenia, with patients showing lower rates of hospital admission and emergency psychiatric care.
• The study analyzed health records of over 70,000 US adults with schizophrenia and type 2 diabetes, finding that those treated with GLP-1 receptor agonists were significantly less likely to require psychiatric acute care compared to those on other diabetes medications or none.
• Mental health benefits were strongest in patients who lost weight but were also observed in those with stable or increased weight, indicating potential weight-independent effects of GLP-1 drugs.
• The drugs, including semaglutide and tirzepatide, may improve mental health by reducing brain inflammation, as supported by previous studies linking GLP-1s to antidepressant and anti-anxiety effects.
• Researchers caution that the study is observational and does not prove causation; GLP-1s should not be prescribed solely for psychiatric treatment, but further clinical trials are needed to explore their role in mental health care.